ECSP12011902A - Compuestos de espiropiperidina como antagonistas - Google Patents

Compuestos de espiropiperidina como antagonistas

Info

Publication number
ECSP12011902A
ECSP12011902A ECSP12011902A ECSP12011902A EC SP12011902 A ECSP12011902 A EC SP12011902A EC SP12011902 A ECSP12011902 A EC SP12011902A EC SP12011902 A ECSP12011902 A EC SP12011902A
Authority
EC
Ecuador
Prior art keywords
antagonists
spiropiperidine compounds
spiropiperidine
compounds
orl
Prior art date
Application number
Other languages
English (en)
Inventor
Buezo Nuria Diaz
Tercero Concepcion Pedregal
Collado Ana Belen Benito
Aguado Alma Maria Jimenez
Blanco Celia Lafuente
Grau Maria Angeles Martinez
Escribano Miguel Angel Toledo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP12011902A publication Critical patent/ECSP12011902A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a un antagonista del receptor ORL-1 de la fórmula:sus usos, y métodos para su preparación.
ECSP12011902 2009-11-16 2012-05-16 Compuestos de espiropiperidina como antagonistas ECSP12011902A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382246 2009-11-16
US29862910P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
ECSP12011902A true ECSP12011902A (es) 2012-07-31

Family

ID=41728051

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011902 ECSP12011902A (es) 2009-11-16 2012-05-16 Compuestos de espiropiperidina como antagonistas

Country Status (34)

Country Link
US (1) US8232289B2 (es)
EP (1) EP2501703B1 (es)
JP (1) JP5680101B2 (es)
KR (1) KR101363830B1 (es)
CN (1) CN102612520B (es)
AR (1) AR078863A1 (es)
AU (1) AU2010319581C1 (es)
CA (1) CA2796161C (es)
CO (1) CO6541545A2 (es)
CR (1) CR20130087A (es)
DK (1) DK2501703T3 (es)
DO (1) DOP2012000135A (es)
EA (1) EA020848B1 (es)
EC (1) ECSP12011902A (es)
ES (1) ES2435814T3 (es)
HN (1) HN2012001011A (es)
HR (1) HRP20130967T1 (es)
IL (1) IL219370A (es)
JO (1) JO2887B1 (es)
MA (1) MA33751B1 (es)
ME (1) ME01537B (es)
MX (1) MX2012005691A (es)
MY (1) MY160665A (es)
NZ (1) NZ600006A (es)
PE (1) PE20121430A1 (es)
PH (1) PH12012500969A1 (es)
PL (1) PL2501703T3 (es)
PT (1) PT2501703E (es)
RS (1) RS53018B (es)
SI (1) SI2501703T1 (es)
TW (1) TWI465453B (es)
UA (1) UA107943C2 (es)
WO (1) WO2011060035A1 (es)
ZA (1) ZA201202967B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2781716A1 (en) 2009-12-04 2011-06-09 Sunovion Pharmaceuticals Inc. Multicyclic thieno compounds and use thereof for the treatment of a neurological disorder
US9394290B2 (en) * 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
TW201416370A (zh) 2012-07-31 2014-05-01 Lilly Co Eli 用於治療焦慮之ｏｒｌ－１受體拮抗劑
RU2641916C2 (ru) 2012-10-02 2018-01-23 Байер Кропсайенс Аг Гетероциклические соединения в качестве пестицидов
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
JO3638B1 (ar) * 2015-09-09 2020-08-27 Lilly Co Eli مركبات مفيدة في تثبيط ror - جاما- t
AU2017301769B2 (en) 2016-07-29 2022-07-28 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
SG10202100751YA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018220509B2 (en) 2017-02-16 2022-04-28 Sumitomo Pharma America, Inc. Methods of treating schizophrenia
EP3589637B1 (en) * 2017-03-02 2021-04-14 Eli Lilly and Company Compounds useful for inhibiting ror-gamma-t
HRP20210898T1 (hr) 2017-03-02 2021-08-20 Eli Lilly And Company SPOJEVI KORISNI ZA INHIBIRANJE ROR-γ-T
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
CA3091292A1 (en) 2018-02-16 2019-08-22 Sunovion Pharmaceuticals Inc. Salts, crystal forms, and production methods thereof
CN113453760B (zh) 2018-12-17 2024-05-24 弗特克斯药品有限公司 Apol1抑制剂及其使用方法
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
CN115734785A (zh) 2020-04-14 2023-03-03 桑诺维恩药品公司 (S)-(4,5-二氢-7H-噻吩并[2,3-c]吡喃-7-基)-N-甲基甲胺用于治疗神经和精神方面的病症
CA3183591A1 (en) 2020-06-12 2021-12-16 Vertex Pharmaceuticals Incorporated Solid forms of apol1 inhibitor and using the same
IL300298B2 (en) 2020-08-26 2025-06-01 Vertex Pharma Inhibitors of apol1 and methods of using same
JP2025505647A (ja) * 2022-02-08 2025-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｐｏｌ１阻害剤としての２－メチル－４’，５’－ジヒドロピロ［ピペリジン－４，７’－チエノ［２，３－ｃ］ピラン］誘導体、およびそれを使用する方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
DE60033071T2 (de) * 1999-12-06 2007-08-23 Euro-Celtique S.A. Triazospiroverbindungen mit nociceptin-rezeptoraffinität
IL158485A0 (en) * 2001-04-18 2004-05-12 Euro Celtique Sa Spiropyrazole compounds
WO2002088089A1 (en) 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
JP4356453B2 (ja) * 2001-07-23 2009-11-04 萬有製薬株式会社 ４−オキソイミダゾリジン−２−スピロピペリジン誘導体
JP2005519921A (ja) * 2002-01-28 2005-07-07 ファイザー株式会社 Ｏｒｌ−１受容体リガンドとしてのｎ置換スピロピペリジン化合物
WO2003095427A1 (en) 2002-05-10 2003-11-20 Taisho Pharmaceutical Co.,Ltd. Spiro-ring compound
US6995168B2 (en) * 2002-05-31 2006-02-07 Euro-Celtique S.A. Triazaspiro compounds useful for treating or preventing pain
US7081463B2 (en) * 2002-09-09 2006-07-25 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders
WO2005016913A1 (en) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
DE10360792A1 (de) * 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
WO2005092858A2 (en) * 2004-03-29 2005-10-06 Pfizer Japan Inc. Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist
DE102004039382A1 (de) * 2004-08-13 2006-02-23 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
PL2260042T3 (pl) * 2008-03-27 2012-02-29 Gruenenthal Gmbh Podstawione spirocykliczne pochodne cykloheksanu

Also Published As

Publication number Publication date
CN102612520B (zh) 2015-04-08
EA020848B1 (ru) 2015-02-27
US20110118251A1 (en) 2011-05-19
HRP20130967T1 (hr) 2013-11-22
PE20121430A1 (es) 2012-10-26
CO6541545A2 (es) 2012-10-16
HN2012001011A (es) 2015-08-31
KR20130026523A (ko) 2013-03-13
NZ600006A (en) 2014-05-30
MY160665A (en) 2017-03-15
MA33751B1 (fr) 2012-11-01
ES2435814T3 (es) 2013-12-23
EP2501703B1 (en) 2013-09-18
PH12012500969A1 (en) 2013-01-07
PT2501703E (pt) 2013-11-26
DK2501703T3 (da) 2013-10-14
DOP2012000135A (es) 2012-08-15
CA2796161C (en) 2015-03-17
AU2010319581B2 (en) 2013-12-19
US8232289B2 (en) 2012-07-31
CN102612520A (zh) 2012-07-25
EP2501703A1 (en) 2012-09-26
SI2501703T1 (sl) 2013-11-29
HK1169988A1 (en) 2013-02-15
KR101363830B1 (ko) 2014-02-14
MX2012005691A (es) 2012-06-13
JO2887B1 (en) 2015-03-15
AU2010319581A1 (en) 2012-06-07
TW201127841A (en) 2011-08-16
CA2796161A1 (en) 2011-05-19
AU2010319581C1 (en) 2014-05-15
EA201290352A1 (ru) 2012-10-30
JP2013510859A (ja) 2013-03-28
ME01537B (me) 2014-04-20
AR078863A1 (es) 2011-12-07
IL219370A0 (en) 2012-06-28
PL2501703T3 (pl) 2014-02-28
CR20130087A (es) 2013-04-17
TWI465453B (zh) 2014-12-21
ZA201202967B (en) 2013-09-25
JP5680101B2 (ja) 2015-03-04
IL219370A (en) 2015-01-29
UA107943C2 (xx) 2015-03-10
RS53018B (sr) 2014-04-30
WO2011060035A1 (en) 2011-05-19

Similar Documents

Publication Publication Date Title
ECSP12011902A (es) Compuestos de espiropiperidina como antagonistas
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
MX2015013711A (es) Novedosas n-acil-(3-sustituidas)-(8-sustituidas)-5,6-dihidro-[1,2, 4]triazolo[4,3-a]piracinas como antagonistas selecticos de receptor de nk-3, composicion farmaceutica y metodos para su uso en trastornos mediados por el receptor de nk-3.
GB2470833A8 (en) Polycyclic antagonists of lysophosphatidic acid receptors.
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
CR20120113A (es) (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer
BR112014000087A2 (pt) derivados de amina cíclica como antagonistas do receptor ep4
MX352881B (es) Metodos y compuestos utiles en la sintesis de antagonistas del receptor de orexina 2.
DOP2013000307A (es) Antagonistas de trpv4
CR20130625A (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
CR20150144A (es) Derivados de etinilo como moduladores del receptor de actividad mglur5
NI201300125A (es) Derivados de 2 - amino - 3 - ( imidazol - 2 - il ) - piridin - 4 - ona y su uso como inhibidores de cinasa del receptor vegf.
DK2606042T3 (da) Disubstituerede tetrahydrofuranyl-forbindelser som antagonister af bradykinin-b1-receptor
BRPI1008008A2 (pt) usos de antagonistas do receptor de nk
CR11828A (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
CO6761385A2 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mglur 2/3
CL2015000038A1 (es) Métodos para preparar triazolopiridinas sustituidas y compuestos intermediarios.
UY34535A (es) Nuevo uso terapéutico de antagonistas del receptor p75.
UY34489A (es) Derivados del ácido cicloalcanocarboxílico como antagonistas del receptor CXCR3
UY34819A (es) Derivados de ß-aminoácido sustituidos como antagonistas del receptor CXCR3.
CU20110003A7 (es) Compuestos novedosos activos como antagonistas de receptor muscarínico
CU20100047A7 (es) Derivados de azaciclilisoquinolinona e-isoindolinona como antagonistas de la histamina-3